In this study, we aimed to investigate 1) serum EGF in oncological patients with a head and neck or lung carcinoma at the time of diagnosis and 2) whether serum EGF could be a potential biomarker for tumour response to chemotherapy and 5-year survival. Here, EGF is linked to lung carcinoma.